^
Association details:
| Biomarker: | EGFR L833V + EGFR H835L |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Gilotrif (afatinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations
Published date:
09/21/2021
Excerpt:
...the effectiveness of afatinib in patients with stage IIIB/IV lung adenocarcinoma...Afatinib demonstrated clinical activity across a set type of specific rare uncommon mutations, including EGFR L747P, A767_V769dup, and L833V/H835L...Our findings suggested that afatinib is effective in patients with uncommon mutations.
DOI:
10.1158/2159-8290.CD-21-0715
